These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload. Janicki JS; Brower GL; Gardner JD; Forman MF; Stewart JA; Murray DB; Chancey AL Cardiovasc Res; 2006 Feb; 69(3):657-65. PubMed ID: 16376324 [TBL] [Abstract][Full Text] [Related]
9. API expert consensus document on management of ischemic heart disease. Association of Physicians of India J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697 [TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases and their inhibitors in non-neoplastic otorhinolaryngological disease. De S; Fenton JE; Jones AS J Laryngol Otol; 2005 Jun; 119(6):436-42. PubMed ID: 15992468 [TBL] [Abstract][Full Text] [Related]
11. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Spinale FG Physiol Rev; 2007 Oct; 87(4):1285-342. PubMed ID: 17928585 [TBL] [Abstract][Full Text] [Related]
12. The role of matrix metalloproteinases in the oral environment. Hannas AR; Pereira JC; Granjeiro JM; Tjäderhane L Acta Odontol Scand; 2007 Feb; 65(1):1-13. PubMed ID: 17354089 [TBL] [Abstract][Full Text] [Related]
13. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 and tissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization. Cevik C; Otahbachi M; Nugent K; Warangkana C; Meyerrose G J Cardiovasc Med (Hagerstown); 2008 Dec; 9(12):1274-8. PubMed ID: 19001938 [TBL] [Abstract][Full Text] [Related]
14. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease. Wu TC; Leu HB; Lin WT; Lin CP; Lin SJ; Chen JW Eur J Clin Invest; 2005 Sep; 35(9):537-45. PubMed ID: 16128859 [TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Galis ZS; Khatri JJ Circ Res; 2002 Feb; 90(3):251-62. PubMed ID: 11861412 [TBL] [Abstract][Full Text] [Related]
16. What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models? Janssens S; Lijnen HR Cardiovasc Res; 2006 Feb; 69(3):585-94. PubMed ID: 16426591 [TBL] [Abstract][Full Text] [Related]